Showing 1301-1310 of 2050 results for "".
- Bausch Health and BHVI Announce Global Licensing Agreement For Myopia Control Contact Lenshttps://modernod.com/news/bausch-health-and-bhvi-announce-exclusive-global-licensing-agreement-for-myopia-control-contact-lens/2478422/Bausch Health has acquired an exclusive license for a myopia control contact lens design developed by BHVI, an Australian not-for-profit organization with an international focus on vision research. Terms of the deal were not disclosed. Bausch + Lomb will pair BHVI’s novel cont
- Ocular Therapeutix Names Namrata Saroj as Chief Business Officerhttps://modernod.com/news/ocular-therapeutix-names-namrata-saroj-as-chief-business-officer/2482536/Ocular Therapeutix announced that Namrata Saroj, OD, has joined the company as Chief Business Officer (CBO). Dr. Saroj, who has been consulting with Ocular since February 2024, brings extensive experience in clinical development and commercialization in ophthalmology. She cont
- RxSight Launches LAL+ and Features Multiple Doctor Presentations at ASCRShttps://modernod.com/news/rxsight-announces-commercial-launch-of-the-lal-and-features-multiple-doctor-presentations-at-ascrs/2482213/RxSight announced the commercial launch of its newest Light Adjustable Lens, the LAL+. The company now offers two lenses in the Light Adjustable Lens platform: the LAL and the Light Adjustable Lens+ (LAL+). The LAL+ has a modified aspheric anterior surface that creates a small cont
- CooperVision Reveals New Ocular Research at ARVO 2021 Virtual Meetinghttps://modernod.com/news/coopervision-reveals-new-ocular-research-at-arvo-2021-virtual-meeting/2479142/CooperVision will present five new research posters as part of the Association for Research in Vision and Ophthalmology (ARVO) 2021 Virtual Meeting, May 1-7. They include original models for evaluating myopia management treatment efficacy as well as emergent physiological factors that affect cont
- Innovent Announces First Patient Dosed in the Phase 2 Clinical Trial of IBI302 Anti-VEGF for Wet AMDhttps://modernod.com/news/innovent-announces-first-patient-dosed-in-the-phase-2-clinical-trial-of-ibi302-anti-vegf-for-wet-amd/2479137/Innovent Biologics announces that the first patient has been successfully dosed in a phase 2 clinical trial for IBI302, a first-in-class ophthalmic recombinant human anti-VEGF and anti-complement bi-specific fusion protein. This study is a randomized, double-blind, multicenter, active-cont
- Johnson & Johnson Vision Launches Tecnis Synergy and Tecnis Eyhance IOLs in Canadahttps://modernod.com/news/johnson-johnson-vision-launches-tecnis-synergy-and-tecnis-eyhance-iols-in-canada/2478160/Johnson & Johnson Vision announced Health Canada approval and July availability of its Tecnis Synergy and Tecnis Eyhance IOLs to the Canadian market. The Tecnis Synergy, originally launched in Europe in September 2019, delivers continuous high-cont
- ARISE-3 Phase 3 Clinical Trial of the RGN-259 for the Treatment of Dry Eye Syndrome is Initiated by ReGenTreehttps://modernod.com/news/arise-3-phase-3-clinical-trial-of-the-rgn-259-for-the-treatment-of-dry-eye-syndrome-is-initiated-by-regentree/2476304/ReGenTree, a joint venture between GtreeBNT and RegeneRx Biopharmaceuticals, announced that it has executed an agreement with Ora for the initiation of ARISE-3 to study the company’s new drug RGN-259 for the treatment of dry eye syndrome. ARISE-3 is a randomized, double masked, placebo cont
- Staar Surgical and Kobe Kanagawa Eye Clinic in Japan Announce Strategic Cooperation Agreementhttps://modernod.com/news/staar-surgical-and-kobe-kanagawa-eye-clinic-in-japan-announce-strategic-cooperation-agreement/2480068/Staar Surgical and Kobe Kanagawa Eye Clinic, with locations in Tokyo and Osaka, announced they have entered into a multi-year Strategic Cooperation Agreement to provide Staar’s EVO Visian ICL lenses as a primary and premium option for patients seeking visual freedom from spectacles and cont
- CORE Highlights Emerging Focus on Pre-Myopia in Latest Contact Lens Updatehttps://modernod.com/news/core-highlights-emerging-focus-on-pre-myopia-in-latest-contact-lens-update/2484173/The Centre for Ocular Research & Education (CORE) has released the newest edition of Contact Lens Update, spotlighting the growing clinical and scientific interest in pre-myopia. This evolving area of study is reshaping how clinicians assess risk, intervene ear
- Generational Differences Drive Contact Lens Choices and Technology Appeal, New Research Findshttps://modernod.com/news/generational-differences-drive-contact-lens-choices-and-technology-appeal-new-research-finds/2484156/The motivations for wearing contact lenses and the appeal of new lens technologies vary significantly by generation, according to new research from the Contact Lens Institute (CLI) to be presented this week at the 2025 American Academy of Optometry annual meet